Combination therapies for hypertension enjoy robust sales

Published: 2013-10-16 06:59:00

Updated: 2013-10-16 06:59:00

Major drug makers, who have been marketing combined formulations of ARB+CCB for the treatment of hypertension, enjoyed robust sales growth last year, industry data showed.

According to the data released by the Ubist, a drug information service agency, Novatis’s Exforge with a combined formulat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK